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a b s t r a c t
Carboplatin, a platinum anticancer drug used to treat many types of human cancer, contains a bidentate dicarboxylate chelate leaving ligand, a structural feature that makes it much less chemically reactive than the ﬁrst-generation platinum anticancer drug cisplatin, which contains two monodentate
chloride leaving ligands. In water, carboplatin exists in a monomer–dimer equilibrium with an association constant of K (M1)  391, a property that accounts for the long-term stability of its readyto-use infusion solution. When administered in the clinic, carboplatin is believed to exert its biological
effects by interacting with genomic DNA and proteins. The slower substitution kinetics of carboplatin,
compared to cisplatin, has prompted investigators to focus on mechanisms by which the compound
can be activated in vivo. Carbonate, which is in equilibrium with hydrogen carbonate, carbonic acid,
and dissolved carbon dioxide, is ubiquitous in biological systems, and is found in high concentrations
in the blood, the interstitial ﬂuid, and the cytosol. Activation of carboplatin by carbonate, CO32
(k1 = 2.04 ± 0.81  10-6 in 24 mM carbonate buffer, pH 7.5 at 37 °C), for example, leads to the formation of platinum species that are more cytotoxic than the parent drug. This short review focuses on
the reason for the unusual stability of carboplatin in its aqueous ready-to-use infusion solution,
describes the reactions of the drug with biologically common nucleophiles and summarizes the activation chemistry that make the drug more reactive toward substances present in the biological
system.
Ó 2012 Elsevier B.V. All rights reserved.
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1. Introduction
Carboplatin, cis-diammine(cyclobutane-1,1-dicarboxylato)platinum(II), Fig. 1, is a platinum anticancer drug used for treating
many types of human cancer [1–5]. While details of its molecular
mechanism of action are not completely known, carboplatin is believed to exert its biological effects by interacting with cellular targets such as genomic DNA, tubulin, and other proteins [6–8].
Carboplatin was developed by Barnett Rosenberg and colleagues
in the early 1970s to improve upon the clinical performance of
the ﬁrst-generation platinum anticancer drug cisplatin, cis-diamminedichloroplatinum(II), Fig. 1 [6,9]. Since carboplatin was found to
be much less oto-, neuro-, and nephrotoxic than cisplatin [1,6,10],
it was ultimately approved as a drug in 1989 under the brand name
Paraplatin.
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Fig. 1. Chemical structures of carboplatin and cisplatin.
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Carboplatin contains a bidentate dicarboxylate chelate leaving ligand, a structural feature that makes the compound much less
chemically reactive than cisplatin [10]. The pseudo-ﬁrst-order rate
constant, k1, for the reaction of carboplatin with water, a reaction
that involves the displacement of one ‘‘arm’’ of the cyclobutane1,1-dicarboxylate (CBDCA) chelate ring from the Pt2+ ion by a water
molecule, spans an unusually wide range, with values of k1 ranging
from approximately 5  10-7 s1 to less than 10-9 s1 at 37 °C [11–
14]. Although there is also discrepancy in the reported rate constant
for the displacement of one of the chloro ligands of cisplatin by water
[12,15], the fact that k1 for the hydrolysis of carboplatin is about two
orders of magnitude smaller than the corresponding hydrolysis rate
for cisplatin has prompted investigators to focus on mechanisms by
which carboplatin may be activated in chemotherapy. This short review focuses on the reason for the unusual stability of carboplatin in
its aqueous ready-to-use infusion solution, describes the reactions
of the drug with biologically common nucleophiles and summarizes
the activation chemistry that make the drug more reactive toward
substances present in the biological system.
2. Self-association of carboplatin in its ready-to-use infusion
solution
The ready-to-use infusion solution of carboplatin contains
10 mg mL1 (approximately 27 mM) platinum complex dissolved
in water alone, water containing mannitol or dextrose, or water
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containing a small amount of the free CBDCA [16,17]. When the
drug is administered to the patient in the clinic, the ready-to-use
infusion solution is diluted in 5% aqueous dextrose or glucose to
the appropriate therapeutic concentration, and the resulting solution is infused into the blood of the patient. A striking feature of the
ready-to-use infusion solution is that the formulation is quite stable, with a shelf-life of 2 years [16]. While some degradation occurs
during this period, it is relatively modest and independent of
excess CBDCA ligand that is present in some formulations [17].
Analysis shows that the degradation products of carboplatin are
ring-opened structures and hydroxo/aqua species not having the
CBDCA ligand. Although the hydrolysis rate constant for carboplatin is easy to measure, the values in the literature span an
unusually large range suggesting that the conditions under which
the rate measurements were made, especially the total concentration of drug in solution, may inﬂuence the rate with which carboplatin reacts with water.
Earlier, we used 110 lM 15N-labeled carboplatin and [1H, 15N]
HSQC NMR to obtain a hydrolysis rate constant for carboplatin of
k1  5  107 s1 (37 °C) [11], which agreed very well with the rate
constant obtained by Brandšteterová et al. at the same temperature using a 300 lM solution of carboplatin [12]. The latter study
also measured the rate constant at 25 °C, ﬁnding agreement with
the value of k1 measured by Tobe and coworkers who used approximately 500 lM drug to study hydrolysis [13]. An unusually small
rate constant of k1 < 109 s1, which is the only reported value that
is consistent with the two year shelf life of the ready-to-use infusion solution of carboplatin, was measured by Sadler and coworkers using 1H NMR and 20 mM drug [14]. While there was no
mention in the early hydrolysis studies involving carboplatin that
the value of k1 may be dependent on the total drug concentration
in solution, it now appears that carboplatin forms an association
dimer in water which, since the dimer resists hydrolysis, is the reason for the high stability of the concentrated ready-to-use infusion
solutions of the carboplatin [18].
A dimer of carboplatin was reported by Burns et al., who used
liquid chromatography–mass spectrometry to analyze a solution
containing approximately 300 lM drug [19]. While the existence
of a dimer was only mentioned in passing in the report, the work
showed that the association complex is stable in a mobile HPLC
phase containing hydrogen-bond disrupting solute molecules. In
another report, Guo and coworkers studied relatively high concentrations of carboplatin (3 mM) using mass spectrometry and reported the existence of a dimer, trimer, and tetramer of the drug
[20]. The dimer of carboplatin was also observed in mass spectroscopic studies by Vivekanandan et al. [21] and later by us [18,22].
Although mass spectrometry is an ideal way to detect association
complexes, solution samples that are injected into the spectrometer are condensed. This can lead to an increase in solute concentration thereby inducing molecular associations that may not be
present under normal solution conditions.
Recently, we used proton NMR to study the self-association of
carboplatin in solution by measuring the integral of the NH resonance at d 4.17 ppm of carboplatin, associated with the two symmetry-equivalent NH3 molecules of the drug, as a function of the
total drug concentration in solution [18]. When the concentration
of carboplatin is high, the NH integral is large and near the value
expected for the compound (6H) but when the concentration of
drug is low, the signal at 4.17 ppm integrates for fewer than six
protons. In order to explain the change in the integral with drug
concentration, it was postulated that carboplatin exists as an association complex at high concentration, the nature of which blocks
the exchange of the NH protons with the protons on solvent. However, at low concentration, the drug exists mainly as a monomer
that has exposed NH protons. These protons rapidly exchange with
the protons of solvent making the NH resonance of the monomer
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unobservable. By ﬁtting the magnitude of the integral as a function
of drug concentration to various association models, it was found
that carboplatin exists in a monomer–dimer equilibrium in water
with an association constant of K (M1)  391. Since the structure
of the dimer prevents exchange of the NH protons with water, it is
also likely to block the attack of water at the Pt2+ ion in hydrolysis,
which is the reason that concentrated solutions of carboplatin are
stable. Using the determined value of K, the ready-to-use aqueous
solution carboplatin (27 mM) contains approximately 81% of the
more stable dimer which is the reason for the long shelf life of
the drug formulation.
A clue that carboplatin can undergo self-association in solution
is evident in the single crystal X-ray structure of the drug that
shows that individual molecules are connected to each other
through an extensive network of intermolecular hydrogen bonds
[23]. In particular, hydrogen bonds exist between the ammonia
molecules of one complex and the oxygen atoms of the dicarboxylate CBDCA ligand of neighboring complexes. Since elements of this
hydrogen bond network could persist in concentrated aqueous
solution, it is easy to see that a drug dimer is possible and, while
dilution would drive the equilibrium toward the more reactive
monomeric form, a small amount of carboplatin dimer could be
present in cell culture studies done with carboplatin, and it could
be circulating in blood (100 lM carboplatin) of patients receiving
carboplatin in chemotherapy [24].

3. Transport of carboplatin
Xie et al. used size exclusion chromatography in combination
with inductively coupled plasma mass spectrometry (SECICP-MS) to measure the kinetics of carboplatin binding to human
serum albumin (HSA) and c-globulin (IgG) in the blood of cancer
patients [25]. While the sites of platinum binding were not determined, the study found that the second-order rate constants for
binding to HSA and IgG are k = 0.74 and 1.01 M1 min1, respectively, at 37 °C, both of which are smaller than the rate constant
for the reaction of cisplatin with HSA. In a more recent study,
Sooriyaarachchi et al. employed size exclusion chromatographyinductively coupled plasma atomic emission (SEC-ICP-AES) to
study the binding of carboplatin to proteins in plasma of healthy
male and female volunteers [26]. The study showed that carboplatin binds to HSA and possibly also to a2-macroglobin with a rate
that is slower than that of cisplatin, with only 40% of carboplatin
being bound to proteins after 24 h.
After passing through the blood, carboplatin appears to enter
the cell through passive diffusion [27,28], although it may enter
via active transport or through ion channels as well [28,29]. Work
done by Osella and coworkers suggests that carboplatin enters the
cell via a passive diffusion mechanism [27]. These authors demonstrated that after 24 h of exposure to carboplatin, the accumulation
ratio (the ratio between intracellular [drug] and extracellular
[drug]) of carboplatin in MCF-7 cells is not dependent on the initial
concentration of drug present in culture medium.
The main copper transporter in human cells is the trans membrane protein, hCtr1. While this protein is important in the transport of copper into the cell, Howell and coworkers suggested that
hCtr1 may also be involved in the transport of platinum drugs
into the cell [30]. An important feature of hCtr1 is its exposed
extracellular portion that contains methionine- and histidine-rich
domains. This region is critical for binding copper and, as has
been suggested, also the platinum drugs for their ultimate
transport into the cell. In an effort to elucidate the transport
mechanism involving hCrt1, Guo and coworkers [31] studied
the interaction of carboplatin, cisplatin and other platinum compounds with a Met- and His-rich 20 mer peptide (hCtr1-N20)
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by peptide donors, transport of carboplatin into the cell via the
copper transporter hCrt1 appears unlikely.
4. Activation of carboplatin
4.1. Chloride and phosphate as activating agents
In an effort to study reactions that carboplatin might undergo in
the body that would provide a basis for activating the drug through
displacement of part or all of the CBDCA ligand, Sadler and coworkers investigated the reaction of carboplatin with chloride and phosphate, which in blood and the cytosol have concentrations of 105
and 5, and 10 and 80 mM, respectively [14,33]. These researchers
found that the pseudo ﬁrst order rate constants at pH 7, 37 °C for
the reaction of carboplatin with chloride and phosphate are
k1 = 7.7  107 s1 and k1 = 4.3 ± 0.2  107 s1, respectively,
showing that under these conditions reaction of carboplatin with
chloride is slightly faster than with phosphate (14). They also
showed that the reaction of carboplatin with chloride produces
cis-[Pt(CBDCA-O)(Cl)(NH3)2], while its reaction with phosphate
produces cis-[Pt(CBDCA-O)(HPO4)(NH3)2]2. Sadler and coworkers
measured similar rate constants for the reaction of carboplatin
with 50 -GMP in the presence and absence of 140 mM chloride in
phosphate buffer, and suggested that activation by chloride, i.e.,
displacement of the CBDCA ligand, is not important in this reaction. Beck and coworkers showed that aging carboplatin in NaCl,
which displaces the CBDCA ligand, produced platinum species that
were more toxic to E. coli PQ37 than was un-aged carboplatin, and
that increasing the incubation time increased the cytotoxicity of
the carboplatin solution [34].

Fig. 2. Speciation in carbonate buffer as a function of pH at 37 °C.

corresponding to the N-terminal domain of hCtr1. Electrospray
ionization (ESI) mass spectrometry (MS) measurements as a function of time showed that carboplatin and cisplatin react with the
Met residues of the peptide and, after initial binding of Met thioether ligands to Pt2+, the bound thioether groups cause the rapid
loss of the cis-ammonia ligands of carboplatin and cisplatin via
the well known trans effect. As expected, the presence of the
CBDCA ligand causes the reaction of carboplatin with the peptide
to be slower than the corresponding reaction with cisplatin and
there was no evidence for a stable ring-opened species in the
reaction of carboplatin with hCrt1-N20.
Franz and coworkers [32] also studied the interaction of carboplatin with peptide fragments having sequences corresponding to
the N-terminal (extracellular) domain of hCrt1. A combination of
liquid chromatography and mass spectrometry conﬁrmed that carboplatin is slower to react than cisplatin with the Met residues of
the peptide. After approximately 48 h, carboplatin completely reacted with the peptide in the process, releasing the CBDCA and
ammonia ligands from the Pt2+ ion of the drug. Since the binding
interaction of carboplatin with hCrt1 is too slow to be clinically relevant and all ligands originally bound to the Pt2+ ion are displaced
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4.2. Activation in carbonate buffer
The most important hydrogen ion controlling buffer in the body
is the carbonate buffer system which has concentrations in blood
and the cytosol of 24 and 12 mM, respectively [35,36]. This buffer consists of dissolved carbon dioxide, CO2, carbonic acid H2CO3,
hydrogen carbonate, HCO3, and carbonate, CO32, all of which are
in equilibrium with one another according to Eq. (1)

CO2 ðaqÞ þ H2 O

HCO3 þ Hþ

H2 CO3

hydroxo

CO2

M

ð1Þ

In aqueous solution, the concentration of dissolved or aquated
carbon dioxide is related to the partial pressure of CO2 in the atmosphere above the solution by Henry’s law, Eq. (2), where KH at 25 °C
is 0.03416 mol kg1 atm1
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Fig. 3. Reactions of carbonate buffer components with metal complexes. (a) Reaction of carbon dioxide with a metal hydroxo complex to produce a hydrogen carbonato
complex. The latter is in proton equilibrium with a carbonato complex that can be mono- or bi-dentate toward the metal ion. (b) Reaction of hydrogen carbonate/carbonate
with a metal complex through a ligand displacement reaction.
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½CO2 ðaqÞ
¼ KH
PCO2

ð2Þ

In biological ﬂuids, some of the dissolved CO2 reacts with water
(see Eq. (1)) to form carbonic acid, H2CO3, according to the equilibrium expression in Eq. (3)

½H2 CO3 
¼ Kx
½CO2 ðaqÞ

ð3Þ

Values of 1/Kx have been reported [37] for NaCl solutions at
temperatures between 15.0 and 32.5 °C. Linear extrapolation of
the results for 27.5–32.5 °C gives Kx = 0.0011145 at 37 °C. Since
Kx is so small, [H2CO3] is small, and often the sum of [CO2] and
[H2CO3] is simply denoted by [CO02 ] or [CO2⁄]. The ﬁrst ionization
constant, Ka = 106.35 at 25 °C, commonly referred to as the acid
ionization constant of carbonic acid H2CO3, actually refers to the
equilibrium in Eq. (4)

½Hþ ½HCO3 
¼ Ka
½CO02 

ð4Þ

Park et al. [38] have measured Ka from 25 to 175 °C and given
pKa as a power series in T, from which we calculate pKa = 6.297
and Ka = 5.049  107 M at 37 °C. Thus, the true acid ionization
constant of carbonic acid is actually given by Eq. (5)

½Hþ ½HCO3
½CO02 
Ka
¼ 4:453  104
¼ Ka

½H2 CO3  K x
½H2 CO3 

ð5Þ

so that pKa(H2CO3) = 3.344. The ionization constant of bicarbonate
is simply Eq. (6)

½Hþ ½CO2
3 
¼ K b ¼ 1010:16
½HCO3 

ð6Þ

where pKb was obtained from the review by Eremenko [39], who
gives recommended values of Kb over a range of temperatures
including 37 °C. By interpolation we derive Kb = 6.87  1011.
Using the values for Kx, Ka, and Kb cited above, one can calculate
the relative amounts of all four species present in a carbonate buffer at equilibrium at any desired pH at 37 °C, Fig. 2. Since these relative amounts (fraction of species on the y-axis) are, of course,
independent of total concentration of carbonate buffer present in
solution, the plot allows the determination of the species distribution in a carbonate buffer as a function of pH. At pH 7.4, the main
carbonate buffer components in blood and the cytosol are

dissolved CO2, 2 and 1 mM, respectively, and hydrogen carbonate, 23 and 11 mM, respectively.
Extensive work has shown that metal complexes containing
bound hydrogen carbonate or carbonate ligands, which can be collectively referred to as ‘‘carbonato complexes’’, can form via rapid
addition of carbon dioxide gas to a metal hydroxo species, Fig. 3a,
or by a slower route involving ligand displacement by carbonate or
hydrogencarbonate, Fig. 3b [40–44]. Second-order rate constants of
37–590 M1 s1 at 25 °C have been reported for the reaction of
dissolved CO2 gas with hydroxo complexes of cobalt, chromium,
iridium, rhodium, and zinc [40], which results in the initial formation of a hydrogen carbonato complex. Depending on the nature of
the metal ion, its charge and the pH of the medium, the initially
formed hydrogen carbonato complex can lose a proton to give a
monodentate carbonato complex or, if the ligand cis to the carbonate is easily displaced, the monodentate carbonate ligand can
attach the metal ion by loss of the cis ligand to form a bidentate
carbonato complex. Since all carbonato complexes are in equilibrium with carbon dioxide gas, if the gas is allowed to escape from
the system, the originally formed carbonato complexes can decompose to their aqua/hydroxo precursors through the loss of CO2,
Fig. 3a [40–45]. Although some hydrogen carbonato complexes
are stable enough to be characterized using X-ray analysis [46],
others, cobalt, iridium, and rhodium [40,45] are unstable, and loose
CO2 with rate constants of 0.25–4.40 s1 at 25 °C.
Using [1H, 15N] HSQC NMR, 1H NMR, 13C NMR and UV-Visible
spectroscopy, we showed that carboplatin reacts with physiological carbonate buffer, to produce platinum-carbonato and -hydroxo
species, Fig. 4 [11,47,48]. Increasing pH at a constant total carbonate concentration, or increasing the total carbonate concentration
at a constant pH, leads to an increase in the rate of reaction of carboplatin in carbonate buffer [11]. Since the concentration of carbonate ion, CO32, increases when either total carbonate or pH
increases, the attacking nucleophile in the ring opening reaction
of carboplatin is carbonate ion which is actually one of the minor
components of the carbonate buffer system at pH 7.4, Fig. 2. Thus,
carboplatin reacts with carbonate ion (k1 = 2.04 ± 0.81  106 in
24 mM carbonate buffer, pH 7.5 at 37 °C) to produce carbonato carboplatin, cis-[Pt(NH3)2(CBDCA-O)(CO3)]2, which is in proton equilibrium with a hydrogen carbonato species, cis-[Pt(NH3)2(CBDCA-O)
(HCO3)]. The latter complex rapidly decarboxylates to the monohydroxo complex, cis-[Pt(NH3)2(CBDCA-O)(OH)]. Although the
latter complex can also be produced by the reaction of carboplatin
with OH, the values of k1 measured using [1H, 15N] HSQC NMR
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show that reaction with hydroxide is less important than the reaction of the drug with carbonate. Once the ring is opened, other
compounds form, including cis-[Pt(NH3)2(CO3)(OH)], which can
also be produced by the reaction of cisplatin in a carbonate buffer
[48,49].
Complete cell culture medium (culture medium plus fetal bovine serum) is similar in composition to blood; thus, studies performed in RPMI culture medium offer insight into the behavior of
carboplatin in vivo. Such studies conﬁrmed that carbonate is one
of the most important nucleophiles in culture medium for the activation of carboplatin [11]. The pseudo-ﬁrst-order rate constant for
the disappearance of the [1H, 15N] HSQC NMR peak for 15N-labeled
carboplatin in complete cell culture medium is approximately 1.5
times larger than that obtained for the disappearance of carboplatin
in medium without carbonate. This disappearance is due to nucleophiles reacting with carboplatin, resulting in species that are ringopened or have the CBDCA ligand completely displaced from the
Pt2+ ion. Chaney and coworkers also recognized the importance of
NaHCO3 as an activating agent by showing that carbonate present
in tissue culture medium can displace the malonate chelate ring
of a Pt2+ antitumor agent structurally related to carboplatin [50].
The mechanistic implications of the activation of carboplatin in
carbonate buffer have also been investigated. Aging carboplatin in
carbonate buffer, pH 8.4–8.6, produces species that are more toxic
to human neuroblastoma (SK-N-SH) and Namalwa-luc Burkitt’s
lymphoma (BL) cancer cells, and proximal renal tubule (HK-2)
cells. We also showed that Jurkat cells that have been made resistant to cisplatin by continual exposure to the drug have reduced
capacity to bind/take up platinum when in contact with solutions
containing signiﬁcant concentrations of carboplatin–carbonate
reaction products [47]. This is probably because the resistant cells
were selected for their ability to survive higher concentrations of
cisplatin, and their survival is associated with mechanisms to prevent platinum from entering cells and/or rapidly removing platinum from cells by an efﬂux mechanism. Since some of the
products shown on the right side of Fig. 4 are the same as those
identiﬁed in the cisplatin system [48,49], and the cells were made
resistant to these species, it is not surprising that the resistant cells
exhibit reduced uptake of the platinum compounds in carbonate
aged carboplatin.
Osella and coworkers also studied the activation of carboplatin
by carbonate, using a DNA-biosensor with a sensing element
capable of immobilizing DNA on the surface of a screen-printed
electrode [51]. In these studies, calf thymus DNA was incubated
with carboplatin in either 24 mM phosphate or carbonate buffers
for various times, the biosensor was dipped into a solution containing platinum, and the amount of Pt binding to the guanine bases on
DNA measured using square wave voltammetry (SWV). The study
showed that in carbonate buffer, carboplatin forms species that can
bind to the guanine bases of DNA. The ability of carbonate buffer to
produce carboplatin species that can bind to and unwind supercoiled DNA has also been reported. When carboplatin is aged in a
carbonate buffer and then added to a 24 mM HEPES (pH 7.4)
buffered solution containing pBR322 DNA, the platinum species
in the medium bind to and unwind supercoiled Form I DNA [52].
Since Form I DNA co-migrates with nicked circular Form II DNA
at some value of r, where r = [drug]/[DNA-bp], the carbonate aged
carboplatin species in the HEPES buffer system act like cisplatin in
that they appear to produce the classic 1,2-intrastrand crosslink on
DNA [8]. However, when the carbonate aged carboplatin species
are reacted with DNA in a two buffer system, 24 mM HEPES plus
24 mM carbonate (pH 7.4) the mobilities of Forms I and II
pBR322 DNA do not change, indicating that the carbonate that is
present in the buffer either blocks the binding of the carbonate
aged carboplatin species to DNA or that binding without a change
in DNA supercoiling occurs.

4.3. Interaction of carboplatin with amino acids
Since sulfur in a thiolate or thioether is considered a soft base
and Pt2+ is a soft acid [53], investigators have focused on the ability
of cysteine and methionine, or peptides and proteins containing
these amino acids, to react with carboplatin [20,54–60]. Sadler
and coworkers showed that the reaction of carboplatin with methionine is rapid, k = 2.7  103 M1 s1 at 25 °C, and results in the
formation of a stable ring-opened species, cis-[Pt(CBDCAO)(NH3)2(L-HMet-S)], which has a long half-life [55]. These authors
suggested that this reaction may play a role in the biological
activity of carboplatin. From this, the rate constant for the reaction
of carboplatin with 0.1 mM L-methionine, the concentration of
L-methionine in RPMI culture medium [50], is approximately
2.7  107 s1. While a thioether group can readily displace the
bidentate chelate ring of carboplatin, the resulting platinum–
methionine adduct is thermodynamically stable, which could
make transfer of the platinum to a target via breakage of the
Pt–S bond difﬁcult [63]. For example, a cis-(NH3)2Pt2+ moiety
which is bound to the terminal Met1 of ubiquitin cannot be transferred to a potential DNA target, 50 -GMP [61]. However, for certain
structures containing both a thioether group and a DNA base, the
initially formed Pt–S adduct can rearrange to the Pt-base adduct
[62]. This suggests that reaction of carboplatin with a thioether
could be a means of activating the drug in vivo. Sheldrick and
coworkers showed that a thioether group in a tripeptide can displace the bidentate dicarboxylate ligand of carboplatin and labilize
the ammonia molecule trans to the thioether-ultimately leading to
the replacement of all of the ligands of carboplatin with donors
from the peptide [58]. Interestingly, although carboplatin reacts
relatively fast with methionine, the reaction of drug with cysteine
is slow [55]; Sadler and coworkers suggested that hydrolysis may
be the rate-limiting step in this reaction [55].
4.4. Interaction with GSH and MT
The two most abundant cellular thiols are glutathione (GSH)
and metallothionein (MT) [63]. Hagrman et al. showed that the
pseudo-ﬁrst-order rate constant for reaction of carboplatin with
6.75 mM GSH in HEPES buffer containing 4.62 mM NaCl, 37 °C, is
k1  9.5 ± 2.8  106 s1 [60]; cells typically contain 2 mM glutathione. The second-order rate constant for the reaction of carboplatin with the fully loaded Cd2+/Zn2+ form of MT in HEPES
buffer containing NaCl, 37 °C, is 0.0121 ± 0.0039 M1 s1 [63].
From these data, the pseudo ﬁrst order rate constant for the reaction of carboplatin with a physiologically relevant concentration of
MT (2 mM) is, k1 8  106 s1. Interestingly, Holler and coworkers showed that the rate of reaction of carboplatin with calf
thymus DNA is signiﬁcantly increased in the presence of L-methionine (thioether), thiourea, and glutathione (thiol), and similar
results were obtained using cytosolic extracts from MCF-7 breast
cancer cells. This suggests that the product of reaction of carboplatin with these sulfur nucleophiles, most likely a Pt2+–S adduct,
can bind to DNA. These observations are consistent with Shi
et al. who showed that the Pt2+ product resulting from the reduction of a Pt4+ complex with GSH is competent to bind to DNA. A
similar conclusion was reached by Volckova et al. who showed that
while, adduct formation is reduced, some cisplatin can bind to DNA
in the presence of GSH. [64,65].
5. Conclusions
In this short review, we discussed the chemistry of carboplatin,
from its remarkable stability in the ready-to-use infusion solution
used in the clinic, to the activation by carbonate and other nucleo-
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philes that makes it more reactive toward substances present in
the cell. Understanding the chemistry of a frequently used drug
like carboplatin is critical for the development of new and
improved platinum-based anticancer agents.
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